SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing intense debate and price volatility following reports of a California court ruling challenging its "Full Self-Driving" branding, raising questions about the company's autonomous technology claims. This fuels widespread discussion, with bears pointing to market overvaluation and FSD limitations, while many bulls remain confident in a rebound to recent highs. The strong contrasting perspectives highlight ongoing investor focus on Tesla's future technology and broader market movements.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is heavily discussed as its earnings report looms, with the community sharply divided between strong bullish expectations driven by soaring AI-related memory demand and fears of a post-earnings sell-off mirroring recent reactions in the broader semiconductor sector. Many believe robust demand and rising memory prices will lead to a strong report, but sector-wide profit-taking after strong earnings remains a key concern.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group (GRRR) is trending following multiple analyst upgrades, notably a "strong-buy" rating from Cantor Fitzgerald with a significant price target, signaling growing confidence in its future. Additionally, an ongoing lawsuit against alleged market manipulators is drawing community attention as a fight to stabilize the stock's valuation. Investors are actively debating the company's substantial contract pipeline and projected revenue growth against concerns over past stock performance and alleged manipulation, with many highlighting GRRR's perceived undervaluation and low float amidst broader AI sector volatility.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Processa Pharmaceuticals is actively trending after announcing positive preliminary Phase 2 data for its NGC-Cap treatment in metastatic breast cancer, demonstrating increased drug efficacy without additional side effects. This crucial update, combined with the company's low share float following a recent reverse split, has fueled intense trading volume and multiple circuit breaker halts. The community is buzzing with bullish sentiment, anticipating substantial price appreciation, though some express caution regarding the stock's volatility and historical patterns.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is experiencing extreme volatility amid speculation surrounding GE Vernova's entry into the fuel cell space and broader market sentiment shifts regarding AI-driven data center spending. The community is sharply divided, with some attributing the sharp price drops to institutional manipulation and tax-loss harvesting, while others see these dips as prime buying opportunities given the company's strong long-term fundamentals in clean energy infrastructure.

Medline, Inc. engages in the provision of medical-surgical products and supply chain solutions. It operates through the Medline Brand and Supply Chain Solutions segments. The Medline Brand segment is involved in the procurement and manufacture of products from surgical solutions, front line care, and laboratory and diagnostics categories. The Supply Chain Solutions segment focuses on procurement and distribution of a variety of third-party products from national brands and provides tailored logistics and supply chain optimization services to domestic and international consumers. The company was founded by Jim Mills and Jon Mills in 1966 and is headquartered in Northfield, IL.

Medline Inc - Ordinary Shares - Class A

Medline Inc.

Medline Inc. ($MDLN) is trending due to its recent, highly anticipated IPO, which was heralded as one of the largest of the year and saw its stock debut with a significant price jump. The community is actively discussing their initial share allocations and the company's future trajectory, balancing its strong position as a medical supply giant and stable cash flows against its notable debt load. Sentiment is mixed, with some holding for long-term growth and others anticipating a potential pullback after the initial market excitement.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is trending following its announcement of a new AI infrastructure partnership with Anthropic and Fluidstack, which includes a substantial data center lease agreement with reported backing from Google. The community is buzzing about this strategic pivot, seeing it as a transformative move from primarily Bitcoin mining into the high-demand AI sector and a catalyst for diversified revenue streams. Many anticipate a significant re-evaluation of the company's future potential.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amidst excitement over a new joint development agreement with a major global automaker, the operational readiness of its 'Eagle Line' manufacturing facility, and its upcoming move to the Nasdaq exchange. Community discussion centers on eagerly anticipated OEM reveals and the company's path to commercialization. While many view these milestones as significant derisking steps, some investors are openly frustrated by the lack of named partners and immediate stock performance despite the positive announcements.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending amidst conflicting reports concerning the financing of its major AI data center project in Michigan. While a financial partner reportedly withdrew, Oracle has swiftly refuted this, asserting the project remains on track with an alternative equity partner, fueling a heated community debate between 'AI bubble' fears over debt and conviction that current negative headlines are 'FUD' creating a buying opportunity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as the technology sector faces significant headwinds, primarily driven by concerns around AI-related capital spending following headlines regarding Oracle's data center financing. Community discussion highlights widespread bearish sentiment, with many questioning the "Santa Rally" as key tech and AI names experience broad selling pressure amid talks of market overvaluation and potential global liquidity shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shares opened well above the offer price, valuing the company at roughly $47 billion after an upsized offering.</li><li>Proceeds are largely being used to reduce debt, with private equity backers partially exiting through the sale.</li><li>The debut marks the largest U.S. IPO since 2021, signaling renewed appetite for large public listings.</li></ul><p>Medline (MDLN) shares surged nearly 30% on Wednesday in their first day of trading, marking a blockbuster debut for the medical-supplies company after it raised $6.26 billion in the largest initial public offering of 2025.</p><p>The stock opened at $35 a share, well above its IPO price of $29, giving Medline a market value of about $47 billion based on shares outstanding disclosed in regulatory filings.</p><h2 class="st-heading-2"><strong>New High For 2025 IPOs</strong></h2><p>Medline sold roughly 216 million shares in an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/medical-supply-giant-medline-upsizes-ipo-and-sets-29-price-ahead-of-wednesday-nasdaq-debut/cLeJprcREpi">upsized offering</a> priced at $29 a share, after increasing the deal size from its earlier filing.</p><p>The IPO surpasses the previous largest listing of the year, a $5.26 billion Hong Kong offering by China’s Contemporary Amperex Technology, and marks the biggest U.S. IPO since Rivian Automotive’s $13.7 billion debut in 2021.</p><h2 class="st-heading-2"><strong>Backers And Use Of Proceeds</strong></h2><p>The company counts Blackstone, Carlyle Group and Hellman &amp; Friedman among its major shareholders.</p><p>Medline said most of the proceeds from newly issued shares will be used to reduce debt and strengthen its balance sheet, with the remainder allocated to general corporate purposes and offering-related expenses. Proceeds from shares sold by existing holders will go toward buying out equity interests from certain pre-IPO owners.</p><h2 class="st-heading-2"><strong>A Medical Supply Giant At Scale</strong></h2><p>Medline describes itself as the largest provider of medical-surgical products and supply-chain services by net sales. Its catalog includes roughly 335,000 products used across hospitals, surgery centers, physicians’ offices and post-acute care facilities.</p><p>About one-third of Medline’s branded products are manufactured in-house across 33 facilities, while the rest are sourced from more than 500 suppliers in around 40 countries. The company also distributes about 145,000 third-party products through its supply-chain services business.</p><h2 class="st-heading-2"><strong>Financial Performance</strong></h2><p>Medline posted $20.6 billion in net sales and $1 billion in profit for the first nine months of 2025. This came after the company reported $25.5 billion in revenue and $1.2 billion in net income in 2024. The company reported that sales have grown annually since its inception and is helped by recurring revenue from long-term customer contracts.</p><p>Prime Vendor agreements, which designate Medline as a primary supplier, generated $16 billion in net sales in 2024. The company said retention under those contracts has averaged more than 98% over the past five years.</p><h2 class="st-heading-2"><strong>IPO Momentum Builds</strong></h2><p>Medline’s strong debut comes as Wall Street attention increasingly turns to the next wave of mega listings. Markets have been buzzing for more than a week around expectations that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/will-spacex-ticker-be-mars-spax-or-sex-polymarket-bets-reveal-odds/cLeO1qrREq9">SpaceX could go public</a> at a valuation of roughly $1.5 trillion, which would make it the largest IPO in history, potentially in mid-to-late 2026.&nbsp;</p><p>SpaceX CEO Elon Musk earlier this week indicated that media reports around the aerospace company’s IPO plans are accurate.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Medline was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:975/149;" src="https://news.stocktwits-cdn.com/mdln_ss_png_91dc8d27a6.webp" alt="mdln ss.png" width="975" height="149"><figcaption>MDLN sentiment and message volume as of December 17| Source: Stocktwits</figcaption></figure><p>One user said, “lezgo! Bought $10K @ $36.62. Let's see where this takes us.”&nbsp;</p><p><stembedurl>https://stocktwits.com/jvbiotek/message/639462113</stembedurl></p><p>Another user predicted that “this share will keep raising, medical equipments are essential business.”&nbsp;</p><p><stembedurl>https://stocktwits.com/x828282/message/639461407</stembedurl></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Medline logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Medline Stock Soars In Debut As Medical Supply Giant Seals 2025’s Biggest IPO

The company's first day on the market underscored strong investor demand for scaled, profitable issuers as the U.S. IPO pipeline shows strength.

Equity

<ul class="summary-bullets"><li>Share count increased from the preliminary filing, with underwriters also granted an option for additional shares.</li><li>Proceeds are earmarked largely for debt repayment and balance sheet strengthening.</li><li>The company enters public markets backed by steady revenue growth and long-term customer contracts.</li></ul><p>Medline Inc. (MDLN) said it has priced its upsized initial public offering at $29 a share after increasing the share count from its earlier filing, clearing the way for the medical-supplies giant to debut on the Nasdaq Global Select Market on Wednesday.</p><p>The company will offer about 216 million Class A shares, up from the 179 million shares outlined in its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/medline-files-for-one-of-2025-s-largest-ip-os-with-potential-valuation-near-55-3-b/cLIpTkjREmU">preliminary filing last week</a>, and has granted underwriters a 30-day option to purchase up to an additional 32.4 million shares. The IPO is expected to close on Thursday.</p><h2 class="st-heading-2"><strong>Use Of Proceeds</strong></h2><p>Medline said most of the proceeds from the IPO will go toward strengthening its balance sheet. The company plans to use the net proceeds from 179 million newly issued shares to repay outstanding debt under its senior secured term loan facilities, with the rest earmarked for general corporate purposes and offering-related expenses.</p><p>Proceeds from another 37 million shares, along with any shares sold if underwriters exercise their option, will be used to buy out an equivalent number of equity interests from certain pre-IPO owners.</p><h2 class="st-heading-2"><strong>Medical Supply Giant At Scale</strong></h2><p>Medline describes itself as the largest provider of medical-surgical products and supply chain services by net sales. Its product catalog spans about 335,000 items used across hospitals, surgery centers, doctors’ offices and post-acute care facilities.</p><p>About one-third of Medline’s branded products are made in-house at 33 manufacturing facilities. The rest are sourced from more than 500 suppliers across roughly 40 countries. Through its Supply Chain Solutions segment, Medline also distributes about 145,000 third-party products and offers inventory and logistics support to customers.</p><h2 class="st-heading-2"><strong>Prime Vendor Relationships Underpin Sales</strong></h2><p>Medline generated $20.6 billion in net sales and $1 billion in profit over the first nine months of 2025, along with $2.7 billion in core profit. In 2024, the company brought in $25.5 billion in revenue and $1.2 billion in net income. Medline said its sales have grown every year since the company was founded, supported by a large base of recurring revenue.</p><p>Prime Vendor agreements, which are long-term contracts under which Medline serves as a primary supplier of medical products, accounted for $16 billion in net sales in 2024. Medline said its Prime Vendor retention rate has averaged more than 98% over the past five years.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Medline was ‘neutral’ amid ‘normal’ message volume.</p><figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/mdln_ss_png_4ccf6a94d8.webp" alt="mdln ss.png" width="972" height="146"><figcaption>MDLN sentiment and message volume as of December 16| Source: Stocktwits</figcaption></figure><p>One user said they likely wouldn’t get their pre-IPO order filled at $30, calling the price too high.</p><p><stembedurl>https://stocktwits.com/six0nine/message/639373037</stembedurl></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

Medical Supply Giant Medline Upsizes IPO And Sets $29 Price Ahead of Wednesday Nasdaq Debut

The IPO features an expanded share count, with proceeds directed toward debt reduction and corporate needs.

<ul class="summary-bullets"><li>Medline plans to sell 179 million Class A shares at $26 to $30 each.</li><li>Major institutional investors signaled interest in buying as much as $2.35 billion of stock.</li><li>Proceeds will be used to buy units of Medline Holdings LP and support debt repayment.</li></ul><p>Medline Inc. (MDLN) set the stage for a major market debut, unveiling a preliminary IPO filing for 179 million Class A shares at an expected price range of $26 to $30.</p><p>The filing did not include a valuation, but Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/medical-supply-firm-medline-aims-raise-54-billion-us-ipo-2025-12-08/">reported</a> the deal could reach $55.3 billion, potentially making it 2025’s biggest IPO. The blockbuster listing is also expected to serve as a key test of investor appetite as markets move toward 2026.</p><p>Underwriters have a 30-day option to buy an additional 26.85 million shares. Members of the Mills family and their affiliates have indicated interest in purchasing as much as $250 million of stock at the offering price. A group of institutional investors including Baillie Gifford, Capital Research, Counterpoint Global, Durable Capital, GIC, Janus Henderson, Viking Global and WCM Investment Management have expressed interest in purchasing up to $2.35 billion of shares.&nbsp;</p><h2 class="st-heading-2"><strong>Use Of Proceeds&nbsp;</strong></h2><p>Medline plans to use the proceeds from the offering to buy newly issued common units from Medline Holdings LP.&nbsp;</p><p>Medline Holdings LP is the operating partnership that owns the business, and Medline Inc. will sit above it as the public company. After the IPO, Medline will have two types of stock, Class A and Class B, and both will carry one vote each. Existing owners hold partnership units in Medline Holdings LP, so they will receive the same number of Class B shares to match those units.</p><p>Medline Holdings will use the funds for debt repayment, general corporate purposes and to cover offering expenses. Any additional proceeds from an underwriter option exercise will be used to buy or redeem equity holdings from certain pre-IPO owners.</p><h2 class="st-heading-2"><strong>Medline’s Supply And Delivery Network</strong></h2><p>Medline describes itself as the largest provider of medical-surgical products and supply chain services based on total net sales. The company’s catalog spans roughly 335,000 medical products used in hospitals, surgery centers, doctors’ offices and post-acute care settings. Medline runs 69 distribution centers worldwide, including 45 in the U.S., with more than 29 million square feet of warehouse space. The network is large enough to provide next-day delivery to about 95% of its U.S. customers.</p><p>Medline manufactures about one-third of its branded products in 33 facilities and sources the rest from more than 500 suppliers across about 40 countries. The company’s Supply Chain Solutions segment distributes 145,000 third-party products and provides inventory and logistics optimization services.</p><h2 class="st-heading-2"><strong>Prime Vendor Relationships Underpin Sales</strong></h2><p>Medline generated $20.6 billion in net sales and $1 billion in profit over the first nine months of 2025, along with $2.7 billion in&nbsp;core profit. In 2024, the company brought in $25.5 billion in revenue and $1.2 billion in net income. Medline said its sales have grown every year since the company was founded, supported by a large base of recurring revenue.</p><p>Prime Vendor agreements accounted for $16 billion in net sales in 2024. Medline said its Prime Vendor retention rate has averaged more than 98% over the past five years.</p><h2 class="st-heading-2"><strong>Commercial Operations</strong></h2><p>The company maintains $4.5 billion in global inventory and operates a fleet of more than 2,000 MedTrans trucks. Medline’s U.S. commercial organization includes about 3,800 employees across sales, clinical support, customer service and supply chain roles.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Medline (MDLN) plans to sell 179 million Class A shares at $26 to $30 each. (Photo credit: Getty Images)

Medline Files For One Of 2025’s Largest IPOs With Potential Valuation Near $55.3B

Medline’s IPO plans outline a 179 million share offering at $26 to $30 with potential demand from major investors indicating a valuation near $55.3 billion.

Medline Announces Public Filing of Registration Statement with the SEC

Medline Announces Public Filing of Registration Statement with the SEC Medline Announces Public Filing of Registration Statement with the SEC PR Newswire NORTHFIELD, Ill., Oct. 28, 2025 NORTHFIELD...

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Stocktwits Polls

Discussion centers on the recent IPO debut, including the offering price, immediate post-debut price action, and widespread experiences with share allocation.

Traders are speculating on the stock's future trajectory, proposing various bullish and bearish price targets following its market debut.

Conversation highlights Medline's robust financial health, impressive sales figures, long-term customer contracts, and essential role as a major medical supply provider.

MDLN
Medline Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest MDLN News

MDLNMedline Inc.